Processa Pharmaceuticals (PCSA) vs Pulmatrix (PULM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Pulmatrix is the larger company by market cap ($4.6 million vs $4.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PCSA | PULM |
|---|---|---|
| Share price | $1.56 | $1.27 |
| Market cap | $4.37M | $4.64M |
| 1-day change | -7.69% | -10.56% |
| EPS (TTM) | $-68.29 | $-1.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-13.56M | $-5.16M |
| 52-week high | $8.88 | $4.94 |
| 52-week low | $1.04 | $1.06 |
| Distance from 52-week high | -82.43% | -74.29% |
| Average volume | 79.50K | 35.45K |
| Shares outstanding | 2.80M | 3.65M |
| Employees | 12 | 2 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Processa Pharmaceuticals
PCSA stock →Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer therapy drugs to improve the safety and efficacy of cancer treatment in the United States. The company's drugs are modifications of existing FDA-approved oncology drugs, resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms for killing cancer cells.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
About Pulmatrix
PULM stock →Pulmatrix, Inc., a biopharmaceutical company, focused on development of novel inhaled therapeutic products to prevent and treat migraine and respiratory diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
PCSA vs PULM FAQ
Which is bigger, Processa Pharmaceuticals or Pulmatrix?
Pulmatrix (PULM) is larger, with a market capitalization of $4.64M compared with $4.37M for Processa Pharmaceuticals (PCSA).
Are Processa Pharmaceuticals and Pulmatrix in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.